Daratumumab in Antibody-Mediated Rejection After Kidney Transplantation: Mechanistic Rationale, Published Clinical Experience, and a Single-Center Case Series
Transplantation Proceedings · 2026-10 · 58 (8) · 1527-1531
DOI: 10.1016/j.transproceed.2026.07.030 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplantation Proceedings, 2026-10. Verfasst von Srilekha Sridhara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Phoenix, Arizona. Electronic address: sridhara.srilekha@mayo.edu. Hauptthemen laut MEDLINE: Kidney Transplantation, Antibodies, Monoclonal, Graft Rejection, Isoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Antibody-mediated rejection (AMR), driven by donor-specific antibodies (DSAs), remains a major cause of kidney allograft dysfunction. Conventional therapies reduce circulating antibodies and target precursor B cells but often fail to eliminate long-lived plasma cells, contributing to persistent or recurrent DSAs. CD38 is highly expressed on antibody-secreting cells, making it a selective therapeutic target for plasma cell depletion. Daratumumab, a fully human anti-CD38 IgG1κ monoclonal antibody, mediates depletion of CD38-expressing cells. OBJECTIVES: Summarize the mechanistic rationale of daratumumab, review published experience with daratumumab in kidney transplantation, and describe a single-center experience using daratumumab for early, refractory AMR. METHODS: We conducted a narrative review of CD38 targeting in AMR and evaluated a retrospective single-center case series of kidney transplant recipients (KTRs) treated with daratumumab after suboptimal response to institutional first-line therapy. Kidney allograft biopsy findings, DSA trajectories, and renal function parameters were trended during follow-up. This study complied with the Declaration of Helsinki and the Declaration of Istanbul; no organs were procured from prisoners or paid donors. RESULTS: Two highly sensitized KTRs developed early acute AMR with persistent DSAs despite first-line therapies. Repeat biopsies demonstrated chronic active AMR (Patient 1) and ongoing/smoldering AMR (Patient 2). Subcutaneous daratumumab was initiated in both patients and there was a durable reduction in DSAs and stabilization or improvement in allograft function. CONCLUSIONS: Daratumumab may serve as an adjunctive option for refractory AMR with persistent DSAs by targeting plasma cell-mediated alloantibody production. Prospective studies are required to define optimal dosing, timing, safety monitoring, and patient selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Mayo Clinic, Phoenix, Arizona. Electronic address: sridhara.srilekha@mayo.edu.
- Division of Nephrology and Hypertension, Mayo Clinic, Phoenix, Arizona.
- Department of Pharmacy, Mayo Clinic, Phoenix, Arizona.
- Department of Lab Medicine and Pathology, HLA Laboratory, Mayo Clinic, Phoenix, Arizona.
- Department of Nephrology and Hypertension, University of Arizona, Tucson, Arizona.
Zitieren
APA
Sridhara, S., Cho, E. L., Nelson, J. E., Khamash, H. A., Alasfar, S., Siegel, R. J., Mour, G. K., Budhiraja, P., Kodali, L., Tanriover, B., & Abu Jawdeh, B. G. (2026). Daratumumab in Antibody-Mediated Rejection After Kidney Transplantation: Mechanistic Rationale, Published Clinical Experience, and a Single-Center Case Series. Transplantation Proceedings, 58(8), 1527-1531. https://doi.org/10.1016/j.transproceed.2026.07.030
Vancouver
Sridhara S, Cho EL, Nelson JE, Khamash HA, Alasfar S, Siegel RJ, et al. Daratumumab in Antibody-Mediated Rejection After Kidney Transplantation: Mechanistic Rationale, Published Clinical Experience, and a Single-Center Case Series. Transplantation Proceedings. 2026;58(8):1527-1531. doi:10.1016/j.transproceed.2026.07.030
BibTeX
@article{Sridhara2026,
author = {Sridhara, Srilekha and Cho, Elizabeth L and Nelson, Joelle E and Khamash, Hasan A and Alasfar, Sami and Siegel, Ruby J and Mour, Girish K and Budhiraja, Pooja and Kodali, Lavanya and Tanriover, Bekir and Abu Jawdeh, Bassam G},
title = {Daratumumab in Antibody-Mediated Rejection After Kidney Transplantation: Mechanistic Rationale, Published Clinical Experience, and a Single-Center Case Series},
journal = {Transplantation Proceedings},
year = {2026},
volume = {58},
number = {8},
pages = {1527--1531},
doi = {10.1016/j.transproceed.2026.07.030}
}
EUVIMED